Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances

NCT00356096 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00356096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00356096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2006
Completion date
Not reported
Enrollment
404 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

depression, restless legs syndrome